Levamisole in the treatment of cyclical neutropenia

S. J. Proctor  
M.B., M.R.C.P.

M. M. Reid  
M.B., D.C.H., M.R.C.P.

W. T. Low  
F.I.M.L.S.

Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne

Summary
A child with cyclical neutropenia was observed before and during treatment with levamisole. Marked clinical improvement occurred while on levamisole. Deterioration occurred after stopping treatment. The improvement was not associated with changes in the neutrophil or monocyte counts, nor did tests of phagocytic cell function convincingly demonstrate improvement while the child was on treatment.

Introduction
Cyclical neutropenia is a rare disease of bone marrow resulting in recurrent infections, especially of the mouth and upper respiratory tract. Verhaegen et al. (1976) suggested previously that levamisole may be of value in the management of this condition. The authors now report the successful use of levamisole in a patient with cyclical neutropenia.

Case report
A 4-year-old Caucasian girl presented with recurrent episodes of mouth ulceration, swollen neck glands and sore throats. Tonsillectomy shortly after presentation resulted in no improvement. Six months later a diagnosis of Behçet's syndrome was suggested. At that time she required drainage of a cervical abscess. At the age of 8 years she was referred to the dentist because of a persistent gingivitis and a blood count showed marked neutropenia. A detailed history revealed that infections and aphthous ulceration occurred regularly at 3- to 4-week intervals but that between these episodes there were no infective problems. A large amount of time had been lost from school and she was taking antibiotics almost continuously. There was no relevant family history. On examination there was marked cervical and submandibular lymphadenopathy and marked aphthous ulceration. She exhibited dermatographia and had suffered from infantile eczema. After 4 months' observation she was given levamisole 50 mg daily for 2 consecutive days each week for 4 months. There was a marked decrease in the severity, although not in the frequency of infections during the period of treatment. No time now was lost from school and antibiotics were used on only 3 occasions. During the next 6 months, treatment with levamisole was discontinued. There was an immediate deterioration with severe aphthous ulceration and episodes of otitis media and conjunctivitis. One week of school was lost 2 months after stopping treatment. Antibiotic requirements rose.

Methods
Phagocytic cell function was assessed on 3 occasions before and once after starting levamisole. The nitroblue tetrazolium (NBT) reduction test was based on the method of Segal and Peters (1975). Results were expressed arbitrarily as spectrophotometer units/10⁶ neutrophils. Chemotaxis was assessed by a method outlined by Wilkinson (1974). Casein was used as the attractant. Results were expressed as the distance in μm travelled by the leading front of cells through the micropore filter. Random migration was similarly assessed in the absence of attractant. Killing ability was assessed by a method based on that of Goldman and Th'ng (1973). Neutrophils and monocytes were incubated with Candida albicans with a C. albicans : phagocyte ratio of 1 : 1. Results were expressed as the percentage of C. albicans killed. On every occasion tests were controlled using cells from one of the laboratory staff. A reference range was derived from data obtained from 20 laboratory staff.

Relative proportions and absolute numbers of T and B lymphocytes were assessed by methods previously described (Reid, Craft and Todd, 1977). Reference ranges were derived from data obtained from 14 children aged 1–14 years admitted for elective surgery.

Results
Figure 1 demonstrates the weekly changes in the neutrophil and monocyte counts before and during

0032-5473/79/0400-0279 $02.00 © 1979 The Fellowship of Postgraduate Medicine
treatment with levamisole. On several occasions the monocyte count was high when neutrophils were virtually absent. Periods of marked neutropenia were usually associated with infective episodes. Haemoglobin, platelets, serum and red cell folate and serum immunoglobulins were all within normal limits. There was a relative lymphocytosis at all times.

Table 1 shows the relative proportions and absolute numbers of peripheral blood T and B lymphocytes measured on 2 occasions while off treatment.

Table 2 shows the results of tests of function of phagocytic cells before and during treatment with levamisole. On occasions, adequate numbers of cells for testing were not obtainable.

**Table 1.** Relative proportions and absolute numbers of T and B lymphocytes

<table>
<thead>
<tr>
<th></th>
<th>T lymphocytes</th>
<th>B lymphocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>No. x 10⁹/l</td>
</tr>
<tr>
<td>Patient</td>
<td>57</td>
<td>2.79</td>
</tr>
<tr>
<td>Normal children*</td>
<td>69±7</td>
<td>2.26±0.6</td>
</tr>
</tbody>
</table>

* Results for normal children expressed as mean ± s.d.

**Discussion**

The history and physical findings conformed closely with the picture of classical cyclical neutropenia. The pattern of neutropenia lent further support to the diagnosis. In this patient, unlike that reported by Verhaegen et al. (1976), periods of monocytosis did occur before treatment with levamisole. Numbers of circulating T lymphocytes were not significantly different from those observed by the authors in normal children. The relative proportions and numbers of circulating B lymphocytes appeared to be increased. This may be partly explained by falsely counting monocytes as B lymphocytes and would explain why the sum of T and B lymphocytes exceeded 100%. Nevertheless, this technical error cannot account for all of the apparent increase in B lymphocytes.

The clinical effect of levamisole is difficult to quantify. However, the subjective impression of improvement was striking to child, mother and observers, as was the deterioration on stopping treatment. No significant changes occurred in neutrophil and monocyte counts after starting levamisole.

Phagocytic cell function was difficult to assess, primarily because such small numbers of cells were involved. NBT reduction was certainly no less efficient

**Table 2.** Phagocytic cell function

<table>
<thead>
<tr>
<th>Nitro blue tetrazolium test (units/10⁶ cells)</th>
<th>Killing ability</th>
<th>Chemotaxis (µm)</th>
<th>Random migration (µm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Off</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levamisole</td>
<td>8.2</td>
<td>25</td>
<td>78</td>
</tr>
<tr>
<td>Normal staff*</td>
<td>12.0 ± 6.3</td>
<td>24 ± 6</td>
<td>109 ± 15</td>
</tr>
</tbody>
</table>

* Results of normal staff are expressed as mean ± 2 s.d.

— not measured owing to insufficient number of cells
Rheumatoid arthritis and lymphocytic infiltration of the phagocytosis system was assessed before treatment only once. This was certainly abnormally low. On retesting after starting treatment a normal result was obtained. However, because of technical difficulties with such small numbers of cells, a convincing improvement of function has not been demonstrated. On 2 occasions, once before and once after starting treatment, monocytes in a monocyte-rich mononuclear cell suspension appeared to kill *C. albicans* as effectively as neutrophils.

Lehner, Wilton and Ivanyi (1976) found that levamisole reduced the incidence of aphthous ulceration. Van Eygen et al. (1976) found that it reduced the incidence of recurrent upper respiratory tract infection in children. Symoens and Rosenthal (1977) have suggested that it influences host defences by modulating cell-mediated immune functions. It restores functions of neutrophils, macrophages and T lymphocytes such as phagocytosis, random migration, chemotaxis, migration inhibition, sheep red cell rosette formation, cell-mediated cytotoxicity and lymphokine production. Significant improvement in phagocytic cell function was not convincingly demonstrated in this patient, although clinical improvement did occur. Since levamisole did not alter the absolute neutrophils or monocyte counts in this patient, it might be reasonable to assume that, in addition to neutropenia, there is in these patients an additional as yet unidentified reduction of phagocytic cell function which it is apparently possible to correct with levamisole.

Finally, Huskisson et al. (1976) reported the development of neutropenia in a patient with rheumatoid arthritis being treated with levamisole, and Williams (1976) reported a case of agranulocytosis in a similar patient. Reports of this nature mean that levamisole, in some patients with rheumatic disorders at least, does have important and potentially hazardous side effects. There was no suggestion of more severe neutropenia in this patient while she was taking the drug. Levamisole may be an effective and safe method of treating this rare but distressing condition.

**Acknowledgment**

M.M.R. was supported by a grant from the Tyneside Leukaemia Research Association.

**References**


Levamisole in the treatment of cyclical neutropenia.

S. J. Proctor, M. M. Reid and W. T. Low

doi: 10.1136/pgmj.55.642.279

Updated information and services can be found at:
http://pmj.bmj.com/content/55/642/279

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/